Requirement to report naxolone dispensations to the CSPMP removed!

On June 21, 2024, Governor Katie Hobbs signed SB1211 into law, which removed the requirement to report naloxone to the CSPMP. This change is effective immediately.

Senate Engrossed Bill

Fact Sheet

Over-the-counter (“OTC”) Naloxone Approved by FDA
The Arizona Board of Pharmacy has drafted a FAQ addressing the recent FDA approval of OTC naloxone. Please see the new OTC Naloxone FAQ.
3D exclaimation point leaning against a wall
Executive Order 2024-03: Protecting Reproductive Freedom Through Increased Access to Contraception
On May 7, 2024, Governor Hobbs signed Executive Order 2024-03: Protecting Reproductive Freedom Through Increased Access to Contraception. The Board of Pharmacy is aware of and reviewing the Executive Order. More information will be posted on the Board's website in the coming days.
bm cap
At its meeting on April 5, 2023, the Board voted to adopt revisions to USP Chapters 795 797, and 800, which are enforceable effective November 1, 2023. At its meeting on August 16, 2023, and after reviewing and discussing the Board's authority to adopt revisions to USP Chapters, the Board voted to rescind its decision and will revisit this topic at a future Task Force Committee on Rule Writing.
Man holding a mask to his face
Beware of scams!
There are individuals posing as Board of Pharmacy employees calling to collect personal information. Please note: The Board of Pharmacy has the information it needs about you in our database. If you receive a call from someone asking for information, DO NOT give out any information until you contact the Board using the phone number on our website to confirm the legitimacy of the call. Read more
PLEASE NOTE: If you receive an email from [email protected], this is a legitimate communication from the Board of Pharmacy and is safe to open.
3D exclaimation point leaning against a wall
Notice of Emergency Rulemaking
Notice of Emergency Rulemaking pertaining to Pharmacy Technician administration of immunizations under Pharmacist delegation and supervision.

August 3, 2022

Update regarding 21 C.F.R. 1306.05(A)

Board staff is receiving calls and emails inquiring about the continued ability for pharmacists to document certain information on prescriptions for schedule II controlled substances, such as patient address.

21 C.F.R. 1306.05(A):

A.R.S. 36-2525:

A federal law enacted in 2019 required all federal agencies to undertake review of various informal guidance documents. As a result of this review, the federal Drug Enforcement Administration ("DEA") removed informal guidance from its website concerning changes to prescriptions for schedule II controlled substances. The National Association of Chain Drug Stores ("NACDS") issued a letter describing a private phone call with DEA officials. The letter indicated that, despite the DEA's historical guidance permitting pharmacist annotations to schedule II controlled substance prescriptions, all prescriptions for schedule II controlled substances must now arrive at the pharmacy with all elements required by 21 C.F.R. 1306.05(A) in final form.

The Arizona State Board of Pharmacy contacted the DEA for guidance on this matter. The DEA was unable to provide further definitive guidance on this topic. If the DEA issues any formal guidance or proposed rule making changes on this matter, Board staff will provide an update.

In the meantime, please direct any questions regarding this matter to:

DEA Office of Diversion Control, Liaison and Policy Section
[email protected]
(571) 362-3260


DEA Prescriptions Q&A (added October 27, 2022)

Need to change your address/employment/PIC?

Need to verify a license, permit, or application?

Complaints / Suspicious Activity / Need To File A Complaint?

ASBP Event Calendar